Cancer vaccines: the next immunotherapy frontier

Lin, Matthew J.; Svensson‐Arvelund, Judit; Lubitz, Gabrielle S.; Marabelle, Aurélien; Melero, Ignacio; Brown, Brian D.; Brody, Joshua

doi:10.1038/s43018-022-00418-6

Cited by 443 publications

(311 citation statements)

References 180 publications

Supporting

Mentioning

308

Contrasting

Unclassified

Order By: Relevance

“…These aforementioned negative studies also raise the possibility that the null hypothesis is in fact validthat adjuvant immunotherapy does not exert a significant impact in the non-metastatic setting. Additionally, it is well known that cytotoxic T lymphocytes require priming by tumor associated antigens on antigen presenting cells [45]. However, most tumor associated antigens are intracellular, rendering them difficult to target [45].…”

Section: U N C O R R E C T E D a U T H O R P R O O Fmentioning

confidence: 99%

“…Additionally, it is well known that cytotoxic T lymphocytes require priming by tumor associated antigens on antigen presenting cells [45]. However, most tumor associated antigens are intracellular, rendering them difficult to target [45]. Thus the exposure of the immune system to these tumor associated antigens seems to be a key event in stimulating a humoral response to tumor in vivo [45].…”

Section: U N C O R R E C T E D a U T H O R P R O O Fmentioning

confidence: 99%

“…However, most tumor associated antigens are intracellular, rendering them difficult to target [45]. Thus the exposure of the immune system to these tumor associated antigens seems to be a key event in stimulating a humoral response to tumor in vivo [45]. This line of reasoning There is now significant interest in molecular char-…”

Section: U N C O R R E C T E D a U T H O R P R O O Fmentioning

confidence: 99%

“…is one of the key drivers behind (1) the development of cancer vaccines, whereby antigens are introduced from an external source, and (2) utilizing radiation to release tumor antigens to parallel the effects of a vaccine[45,46]. Under this hypothesis, the absence ofvisible tumor in these adjuvant RCC trials would significantly attenuate antigen presentation and thus may be postulated to shed light on biologic mechanisms underlying the relative inefficacy of these adjuvant trials.…”

mentioning

confidence: 99%

See 3 more Smart Citations

Adjuvant Therapy in Renal Cell Carcinoma: Are We Ready for Prime Time?

Wang

Saidian

Pan

et al. 2023

KCA

View full text Add to dashboard Cite

The standard of care for localized renal cell carcinoma (RCC) is radical or partial nephrectomy. Despite complete resection, a subset of patients will develop locoregional recurrence or metastatic disease. Adjuvant immunotherapy has been studied since the 1980 s as the primary method to mitigate tumor recurrence after definitive surgery. We herein discuss published and ongoing clinical trials investigating adjuvant therapy in localized or locoregional RCC.

show abstract

Section: U N C O R R E C T E D a U T H O R P R O O Fmentioning

confidence: 99%

Section: U N C O R R E C T E D a U T H O R P R O O Fmentioning

confidence: 99%

Section: U N C O R R E C T E D a U T H O R P R O O Fmentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Adjuvant Therapy in Renal Cell Carcinoma: Are We Ready for Prime Time?

Wang

Saidian

Pan

et al. 2023

KCA

View full text Add to dashboard Cite

show abstract

“…Depending on the type of protein, surface protein–protein interactions can either stimulate or inhibit T cell recruitment induction. T cells are activated when the antigen presented by HLA also interacts with the TCR simultaneously [ 32 , 40 ]. However, cancer is a complex illness in which immunosuppressive cells in the tumor microenvironment, such as regulatory T cells (Treg) and myeloid-derived suppressor cells (MDSCs), moderate the immune response and help cancer cells escape the immune system [ 41 ].…”

Section: Immune Response To Epitope-based Peptide Vaccinementioning

confidence: 99%

Immunoinformatics Approach for Epitope-Based Vaccine Design: Key Steps for Breast Cancer Vaccine

2022

View full text Add to dashboard Cite

Vaccines are an upcoming medical intervention for breast cancer. By targeting the tumor antigen, cancer vaccines can be designed to train the immune system to recognize tumor cells. Therefore, along with technological advances, the vaccine design process is now starting to be carried out with more rational methods such as designing epitope-based peptide vaccines using immunoinformatics methods. Immunoinformatics methods can assist vaccine design in terms of antigenicity and safety. Common protocols used to design epitope-based peptide vaccines include tumor antigen identification, protein structure analysis, T cell epitope prediction, epitope characterization, and evaluation of protein‒epitope interactions. Tumor antigen can be divided into two types: tumor associated antigen and tumor specific antigen. We will discuss the identification of tumor antigens using high-throughput technologies. Protein structure analysis comprises the physiochemical, hydrochemical, and antigenicity of the protein. T cell epitope prediction models are widely available with various prediction parameters as well as filtering tools for the prediction results. Epitope characterization such as allergenicity and toxicity can be done in silico as well using allergenicity and toxicity predictors. Evaluation of protein‒epitope interactions can also be carried out in silico with molecular simulation. We will also discuss current and future developments of breast cancer vaccines using an immunoinformatics approach. Finally, although prediction models have high accuracy, the opposite can happen after being tested in vitro and in vivo. Therefore, further studies are needed to ensure the effectiveness of the vaccine to be developed. Although epitope-based peptide vaccines have the disadvantage of low immunogenicity, the addition of adjuvants can be a solution.

show abstract

Immunotherapeutic Hydrogel with Photothermal Induced Immunogenic Cell Death and STING Activation for Post‐Surgical Treatment

Wang

Zhang

Liu

et al. 2023

Adv Funct Materials

View full text Add to dashboard Cite

Post-surgical tumor recurrence remains a major clinical concern for patients with malignant solid tumors. Herein, an immunotherapeutic hydrogel (SA PBA / ZMC/ICG) is developed by incorporating metal ion-cyclic dinucleotide (CDN) nanoparticles (Zn-Mn-CDN, ZMC) and a photosensitizer (indocyanine green, ICG) into phenylboronic acid (PBA)-conjugated sodium alginate (SA PBA ) for photothermal therapy (PTT)-triggered in situ vaccination to inhibit post-surgical recurrence and metastasis of malignant tumors. The gelation of SA PBA / ZMC/ICG in the residual tumors can achieve accurate local PTT and the local sustained release of CDN and Mn 2+ with minimal detrimental off-target toxic effects. Furthermore, CDN, which is an agonist of the stimulator of interferon genes (STING), along with Mn 2+ can activate the STING pathway and trigger type-I-IFN-driven immune responses against tumors. Therefore, the immunotherapeutic hydrogel with enhanced immune response by STING agonist and PTT-induced immunogenic cell death (ICD) reprograms the post-surgical immunosuppressive microenvironment, substantially decreasing the postsurgical recurrence and metastasis of solid tumors in multiple murine tumor models when administered during surgical resection. Taken together, PTTtriggered and STING-mediated in situ cancer vaccination is an effective therapeutic intervention for post-surgical recurrence and metastasis of tumors.

show abstract

Cancer vaccines: the next immunotherapy frontier

Cited by 443 publications

References 180 publications

Adjuvant Therapy in Renal Cell Carcinoma: Are We Ready for Prime Time?

Adjuvant Therapy in Renal Cell Carcinoma: Are We Ready for Prime Time?

Immunoinformatics Approach for Epitope-Based Vaccine Design: Key Steps for Breast Cancer Vaccine

Immunotherapeutic Hydrogel with Photothermal Induced Immunogenic Cell Death and STING Activation for Post‐Surgical Treatment

Contact Info

Product

Resources

About